CEO Interview: AstraZeneca's David Brennan
Executive Summary
David Brennan has sharpened AstraZeneca's therapeutic area focus and embraced external R&D. The next two years will determine whether the productivity drive is working--or if more radical change is needed.
You may also be interested in...
AZ Joins Spin-Out Set, Forms GI Play Albireo
AstraZeneca has completed its first ever biotech spin out, creating the Swedish biotech firm Albireo with backing led by Nomura Phase4 Ventures. The deal underscores pharma's disenchantment with certain aspects of GI drug development and may blaze a trail for other non-core areas of R&D at the drugmaker.
Can Amgen Find a New Engine?
Amgen's string of misfortunes has highlighted the group's need to find an alternative growth engine--one which will, necessarily, look very different from the current anemia franchise. The biotech is leaning too heavily on osteoporosis and cancer candidate denosumab.
Reviewing Five Years of Big Pharma's Biotech Acquisitions
A review of the past five years' significant ($100mm or greater) pharma-biotech acquisitions among the industry's largest players illustrates Big Pharma's diverging M&A strategies, and why there's more to come. We examine who's buying and how much has been spent, and take a look at who has succeeded in getting value (and pipeline) for money.